Peter M. Kash is Director at Nile Therapeutics, Inc. (NLTX). They have made 3 open-market trades across 3 companies since 2006, most recently 2008-12-12.
CIK 0001253023
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $24K since 2006, never a sale. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.